News | July 27, 2021
GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
National conference brings together 160+ experts from six states to advance blood quality and safety standards
The resolution significantly reduces a long-standing contingent liability from the company's books
Industry members have until 15 July 2026 to submit feedback on proposals seeking additions, deletions and modifications to the Global Tender Enquiry
The collaboration comes at a time when access to high-quality fertility treatment remains uneven, despite rapid market expansion
Partnership with Duopharma Biotech covers human insulin, insulin glargine and insulin aspart, supporting diabetes care and medicine security in Malaysia
Subscribe To Our Newsletter & Stay Updated
